AUPH inside days after good run up. $AUPH AUPH inside days after good run up and decent beat. Liquid and increasing institutional interest.
−0.51USD
−108.18MUSD
134.03MUSD
130.216M
About Aurinia Pharmaceuticals Inc
Sector
Industry
CEO
Peter S. Greenleaf
Website
Headquarters
Edmonton
Employees (FY)
300
Founded
1993
ISIN
CA05156V1022
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
AUPH Inverse H&SPrice has broken out of a down channel
I see this breaking down slightly back into the channel, forming a right shoulder along the yellow horizontal and then continuing to pursue the reversal above the channel
Lets see what happens on this Weekly chart
Bars pattern in green shows my idea
AUPH: Bulls set to take controlAfter a month of sideways chop, perfectly contained by 7.67 & 6.99 (ORANGE), we now have a path towards higher levels at 10.23 (RED dotted line). S/R's.
Reversal off supportMarket trading sideways, strong $10 support level. High volume candle with long lower wick rejecting support. RSI at potential double bottom level. Historic support level, showing high potential for reversal to the bull side.
Head and Shoulders projects $9.5-10.50 consolidation zone
41% retracement from head to neckline, so 41% from neckline puts it at $10.50. There are multiple horizontal support zones, see chart that also correspond to this zone $9.50 - 10.50. Greenleaf (CEO) is a complete clown. Issuing a statement last week that guidance will likely be aggressive then
$AUPH 200MA broken, Pivot points used to calculate R:R.Noticed Auph broke the 200ma did some quick analysis which means jack all but if we continue on this upward trend were likely to see a breakout soon. TA is based on pivot points with supports. Box means support confirmed over a few candles, ellipses is looking for past supports. This isn't investmen
Aurinia Announces Positive Topline Results From the AURORA 2 ConAUPH: Aurinia Pharmaceuticals Inc.
2021-12-09 06:15:00
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
